Investor Relations

Platform

At the core of Medicenna’s therapies are interleukins (IL-2, IL-4 and IL-13), which are engineered to be highly specific and fused with other molecules to enhance their function. In doing so, they become powerful and proprietary tools called Superkines that can modulate, fine-tune and empower the immune system to fight cancer, autoimmune and neuroinflammatory diseases.

Minimum 15 minutes delayed. Source: LSEG

SEC Filings

Featured SEC Filings
Filing Date Description Form
Notice of Exempt Offering of Securities D
15-12G     15-12G
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act 6-K